Biogen Idec (BIIB) races to a 8.7% gain premarket after announcing positive top-line results...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen Idec (BIIB) races to a 8.7% gain premarket after announcing positive top-line results from a second Phase 3 trial of its BG-12 MS treatment. The study showed the risk of patients falling into relapse was reduced after taking the BG-12 pill.